Histology
Squamous Cell Carcinoma
CI-CAN-00001550SCCExplore in graph →
977 active trials9 approved drugs78 evidence items
Loading cancer entity…
Loading cancer entity…
Histology
CI-CAN-00001550SCCExplore in graph →
Clinical trials
2,930 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (401)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06876038 | Low-cost Screening and Image-guided Photodynamic Therapy (PDT) of Premalignant and Malignant Oral Lesions | not yet recruiting | Phase 2 | 65 | University of Massachusetts, BostonOTHER | 1 | Mar 19, 2026 | clinicaltrials |
| NCT07482774 | Tumor Microenvironment Changes After Neoadjuvant Chemo-Immunotherapy in Esophageal Squamous Cell Carcinoma(TME-ESCC) | not yet recruiting | — | 12 | Nanjing Medical UniversityOTHER | 0 |
| Mar 19, 2026 |
| clinicaltrials |
| NCT07469241 | Study of MRI Guided Personal Chemoradiotherapy and Immunotherapy for Limited Advanced Esophageal Squamous Caicinoma.(FUTURE-3) | not yet recruiting | Phase 2 | 50 | Fudan UniversityOTHER | 0 | Mar 13, 2026 | clinicaltrials |
| NCT07471009 | Development of Patient Derived Xenografts (PDXs) and Analysis of Tyrosine Kinase Receptor Expression in Patients With Squamous Cell Head and Neck Cancer (HNSCC) to Study Resistance Mechanisms Induced by Standard Therapy(SPAR) | not yet recruiting | — | 120 | IRCCS Azienda Ospedaliero-Universitaria di BolognaOTHER | 1 | Mar 13, 2026 | clinicaltrials |
| NCT07457099 | Impact of Postoperative Radiotherapy Versus PD-1 Inhibitor Maintenance on Survival in Resectable Locally Advanced Oral and Oropharyngeal Squamous Cell Carcinoma | not yet recruiting | — | 85 | Zhujiang HospitalOTHER | 1 | Mar 9, 2026 | clinicaltrials |
| NCT07446335 | A Phase III Study of First-line Anlotinib Combined With Benmelstobart in Patients With Advanced Esophageal Squamous Cell Carcinoma | not yet recruiting | Phase 3 | 578 | The First Affiliated Hospital of Zhengzhou UniversityOTHER | 1 | Mar 3, 2026 | clinicaltrials |
| NCT07432087 | Camrelizumab Combined With EGFR Monoclonal Antibody or Chemotherapy for Perioperative Treatment of Locally Advanced Head and Neck Squamous Cell Carcinoma | not yet recruiting | Phase 3 | 246 | Yue He, MDOTHER | 0 | Feb 25, 2026 | clinicaltrials |
| NCT07428148 | Lattice-Based Radiotherapy and Chemoimmunotherapy for Oropharyngeal Squamous Cell Carcinoma | not yet recruiting | Phase 1 / Phase 2 | 60 | NYU Langone HealthOTHER | 1 | Feb 23, 2026 | clinicaltrials |
| NCT07403435 | Short-course Radiotherapy Combined With Serplulimab and Chemotherapy as Neoadjuvant Treatment for Resectable ESCC | not yet recruiting | Phase 2 | 22 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | Feb 11, 2026 | clinicaltrials |
| NCT07400094 | Neoadjuvant Chemoimmunotherapy (Camrelizumab + Paclitaxel + Carboplatin) for Resectable HNSCC(NeoCamre-HN) | not yet recruiting | Phase 2 | 50 | National Medical Research Radiological Centre of the Ministry of Health of RussiaOTHER | 1 | Feb 10, 2026 | clinicaltrials |
| NCT07392073 | Peripheral Blood ETASTs for Predicting Efficacy of Chemoimmunotherapy in NSCLC | not yet recruiting | — | 80 | Shanghai General Hospital, Shanghai Jiao Tong University School of MedicineOTHER | 0 | Feb 6, 2026 | clinicaltrials |
| NCT07393477 | Neoadjuvant Becotatug Vedotin Plus Pucotenlimab and Cisplatin for Locally Advanced Head and Neck Squamous Cell Carcinoma | not yet recruiting | Phase 2 | 30 | Sir Run Run Shaw HospitalOTHER | 1 | Feb 6, 2026 | clinicaltrials |
| NCT07394244 | Pucotenlimab Combined With Becotatug Vedotin in Advanced Cutaneous Squamous Cell Carcinoma | not yet recruiting | Phase 2 | 38 | Fudan UniversityOTHER | 1 | Feb 6, 2026 | clinicaltrials |
| NCT07384078 | High Intensity Focused Ultrasound vs. Cryotherapy in the Treatment of Basal Cell Carcinomas and Bowen's Disease in Adults(HIFUvsCRYO) | not yet recruiting | N/A | 294 | Jussi SalonenOTHER | 1 | Feb 3, 2026 | clinicaltrials |
| NCT07384949 | Correlation of Dermoscopic Findings With Histopathological Features and Invasion Depth in Cutaneous Squamous Cell Carcinoma(SCC-DERM) | not yet recruiting | — | 238 | Istanbul Training and Research HospitalOTHER_GOV | 1 | Feb 3, 2026 | clinicaltrials |
| NCT06952621 | Neoadjuvant Treatment of Toripalimab Combined With Nab-paclitaxel and Platinum Versus Neoadjuvant Docetaxel Combined With Cisplatin and 5-fluorouracil (DCF) in Esophageal Squamous Cell Carcinoma(TD-NEOE3V3) | not yet recruiting | Phase 3 | 390 | Tang-Du HospitalOTHER | 1 | Jan 30, 2026 | clinicaltrials |
| NCT07379424 | A Single-arm, Phase II, Multi-center Clinical Trial of Sintilimab During the Perioperative Period in Patients With Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma | not yet recruiting | Phase 2 | 37 | chen chao ProfessorOTHER | 1 | Jan 30, 2026 | clinicaltrials |
| NCT07335380 | Lattice-Based Radiotherapy and Chemo-Immunotherapy for Oral Cavity Squamous Cell Carcinoma | not yet recruiting | Phase 1 | 30 | NYU Langone HealthOTHER | 1 | Jan 29, 2026 | clinicaltrials |
| NCT07376876 | Indocyanine Green-guided Omental Shield Anastomosis for Cervical Esophagogastric Anastomosis in Minimally Invasive McKeown Esophagectomy | not yet recruiting | Phase 2 | 73 | Daping Hospital and the Research Institute of Surgery of the Third Military Medical UniversityOTHER | 1 | Jan 29, 2026 | clinicaltrials |
| NCT07371897 | Toripalimab ± Chemo as Neoadjuvant Therapy in LA-HNSCC: A Phase III Trial(SHINE) | not yet recruiting | Phase 3 | 154 | Sun Yat-sen UniversityOTHER | 0 | Jan 28, 2026 | clinicaltrials |
| NCT07361666 | Impact of Preoperative High-Frequency Ultrasound Cutaneous Lesion Extent Assessment on Excision Margin Positivity in Head and Neck Skin Cancer, and the Relationship Between Preoperative Assessment Methods, Inadequate Excision Margins, and Tumor Recurrence(HFUS-CLEAR) | not yet recruiting | — | 400 | Państwowy Instytut Medyczny Ministerstwa Spraw Wewnętrznych i AdministracjiOTHER_GOV | 1 | Jan 23, 2026 | clinicaltrials |
| NCT07358884 | First in Human Study of QLS5316 in Solid Tumors | not yet recruiting | Phase 1 | 300 | Qilu Pharmaceutical Co., Ltd.INDUSTRY | 0 | Jan 22, 2026 | clinicaltrials |
| NCT07354984 | A Single-Arm Phase II Clinical Study of Docetaxel Combined With Nimotuzumab and Pucotenlimab as Second-Line and Beyond Therapy for Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma(PIONEER-HN) | not yet recruiting | Phase 2 | 30 | Sun Yat-sen UniversityOTHER | 1 | Jan 21, 2026 | clinicaltrials |
| NCT07346196 | A Trial of Locoregionally Advanced Squamous Cell Carcinoma of The Head and Neck | not yet recruiting | Phase 2 | 90 | University of ChicagoOTHER | 1 | Jan 20, 2026 | clinicaltrials |
| NCT07353541 | Standardized Management of Esophageal Fistula in Esophageal Squamous Cell Carcinoma(PKU-ESCC-EF) | not yet recruiting | — | 32 | Peking University Cancer Hospital & InstituteOTHER | 0 | Jan 20, 2026 | clinicaltrials |
| NCT07346807 | Lingual Nerve Disruption to Augment Neoadjuvant Chemoimmunotherapy in Locally Advanced Tongue Cancer | not yet recruiting | Phase 2 | 69 | Shanghai Zhongshan HospitalOTHER | 1 | Jan 16, 2026 | clinicaltrials |
| NCT07343869 | Multicenter Prospective Cohort on Esophageal Endoscopic Submucosal Dissection(FEO) | not yet recruiting | — | 750 | Société Française d'Endoscopie DigestiveOTHER | 1 | Jan 15, 2026 | clinicaltrials |
| NCT07320690 | De-Escalation Surgery After Immunotherapy in Locally Advanced Head and Neck Squamous Cell Carcinoma(Neo-Margin) | not yet recruiting | Phase 3 | 356 | Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong UniversityOTHER | 1 | Jan 6, 2026 | clinicaltrials |
| NCT07310771 | Sintilimab-Nimotuzumab Induction Followed by Chemoradiation-Nimotuzumab in LA-HNSCC: Single-Arm Phase II | not yet recruiting | Phase 2 | 23 | Fujian Cancer HospitalOTHER_GOV | 0 | Dec 30, 2025 | clinicaltrials |
| NCT07306546 | Effectiveness of Hydrogen Water Intervention on Acute Oral Inflammation, Oral Microbiota, and Pain Following Free Flap Reconstruction in Patients With Oral Cancer | not yet recruiting | N/A | 36 | Kaohsiung Medical University Chung-Ho Memorial HospitalOTHER | 0 | Dec 29, 2025 | clinicaltrials |
| NCT07272291 | A Phase II Study of Toripalimab Plus Chemotherapy and Low-Dose Radiotherapy for Neoadjuvant Therapy-Refractory Esophageal Squamous Cell Carcinoma | not yet recruiting | Phase 2 | 48 | Tianjin Medical University Cancer Institute and HospitalOTHER | 0 | Dec 9, 2025 | clinicaltrials |
| NCT07259915 | Multimodal Prediction of Response to Chemoradiotherapy for Squamous Cell Carcinoma of the Head and Neck(MULTINECK) | not yet recruiting | N/A | 152 | Centre Henri BecquerelOTHER | 1 | Dec 2, 2025 | clinicaltrials |
| NCT07251062 | A Study of SYS6010, Enlonstobart, and Chemotherapy for First-Line Treatment of Esophageal Squamous Cell Carcinoma. | not yet recruiting | Phase 2 / Phase 3 | 737 | CSPC Megalith Biopharmaceutical Co.,Ltd.INDUSTRY | 0 | Nov 26, 2025 | clinicaltrials |
| NCT07246330 | Stratified Treatment in Unresectable Locally Advanced ESCC Without Progression After Chemoimmunotherapy Induction Plus CCRT: Toripalimab Consolidation vs observation--a Prospective, Randomized, Controlled Phase III Multicenter Study | not yet recruiting | Phase 3 | 340 | Tianjin Medical University Cancer Institute and HospitalOTHER | 0 | Nov 24, 2025 | clinicaltrials |
| NCT07246759 | Neutrophil Biomarker Test for Predicting Clinical Benefit From Immunotherapy Based on Flow Cytometry Analysis(NEUTROFLOW) | not yet recruiting | — | 600 | OncoHost Ltd.INDUSTRY | 3 | Nov 24, 2025 | clinicaltrials |
| NCT07203898 | A Study of IPM514 in Patients With Esophageal Squamous Cell Carcinoma. | not yet recruiting | Phase 1 | 36 | Beijing Immupeutics Medicine Technology LimitedINDUSTRY | 0 | Oct 2, 2025 | clinicaltrials |
| NCT07152535 | Multi-omics Monitoring of Dynamic Evolution in Esophageal Squamous Cell Carcinoma: PKU-ESCC-Monitor(PKU-ESCC) | not yet recruiting | — | 255 | Peking University Cancer Hospital & InstituteOTHER | 0 | Sep 3, 2025 | clinicaltrials |
| NCT06989671 | SYS6002 Plus JMT101 and Enlonstobart Injection in Participants With HNSCC | not yet recruiting | Phase 2 | 430 | CSPC Megalith Biopharmaceutical Co.,Ltd.INDUSTRY | 0 | Aug 27, 2025 | clinicaltrials |
| NCT07135804 | Iparomlimab and Tuvonralimab Injection for Untreated Locally Advanced Nasopharyngeal Carcinoma | not yet recruiting | Phase 2 | 45 | Second Affiliated Hospital of Nanchang UniversityOTHER | 0 | Aug 22, 2025 | clinicaltrials |
| NCT07137858 | Adebrelimab Combined With Carboplatin and Albumin-bound Taxanol in the Treatment of Resectable Locally Advanced Oral Squamous Cell Carcinoma Cardiac, Randomized, Phase II Exploratory Study | not yet recruiting | Phase 2 | 70 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 0 | Aug 22, 2025 | clinicaltrials |
| NCT07128693 | A Single-center, Multicohort, Phase II Clinical Study Evaluating the Combination Therapy of Sacituzumab Tirumotecan in Patients With Unresectable, Locally Advanced, Recurrent, or Metastatic Esophageal Squamous Cell Carcinoma | not yet recruiting | Phase 2 | 60 | The First Affiliated Hospital of Zhengzhou UniversityOTHER | 0 | Aug 19, 2025 | clinicaltrials |
| NCT07112833 | A Phase II Clinical Study of Induction Adebrelimab Combined With Chemotherapy Followed by Concurrent Chemoradiotherapy for Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma (ESCC) | not yet recruiting | Phase 2 | 36 | Hebei Medical University Fourth HospitalOTHER | 1 | Aug 8, 2025 | clinicaltrials |
| NCT07090707 | PD-1 Inhibitor Therapy Versus Radiotherapy in MPR Patients With Locally Advanced HNSCC After Neoadjuvant Immunochemotherapy (HNC-SYSU-006) | not yet recruiting | Phase 2 | 50 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Jul 29, 2025 | clinicaltrials |
| NCT07079410 | Neoadjuvant and Adjuvant Sintilimab Plus Cetuximab in Locally Advanced Oral and Oropharyngeal Squamous Cell Carcinoma(OSCC) | not yet recruiting | Phase 2 | 50 | Shanghai Zhongshan HospitalOTHER | 1 | Jul 23, 2025 | clinicaltrials |
| NCT07067450 | Adjuvant Immunotherapy for Esophageal Squamous Cell Carcinoma | not yet recruiting | N/A | 98 | Sichuan UniversityOTHER | 0 | Jul 16, 2025 | clinicaltrials |
| NCT07049185 | QL1706 Plus Celecoxib in Advanced Esophageal Squamous Cell Carcinoma(QICE-ESCC) | not yet recruiting | Phase 2 | 35 | Peking University Cancer Hospital & InstituteOTHER | 0 | Jul 3, 2025 | clinicaltrials |
| NCT07036185 | A Clinical Trail of KJ015 in Patients With HER2-Expressing Solid Tumors | not yet recruiting | Phase 1 | 66 | Shanghai Bao Pharmaceuticals Co., Ltd.INDUSTRY | 1 | Jun 25, 2025 | clinicaltrials |
| NCT07028918 | A Prospective Single-Arm Study（NCLDR）(NCLDR) | not yet recruiting | Early Phase 1 | 35 | Qilu Hospital of Shandong UniversityOTHER | 0 | Jun 19, 2025 | clinicaltrials |
| NCT07009925 | Phase II Study of Platinum (Cisplatin/Carboplatin)and Polymeric Micelles Paclitaxel(Pm-Pac) With Ivonescimab in First Line Metastatic Squamous NSCLC. | not yet recruiting | Phase 2 | 38 | Jiangsu Cancer Institute & HospitalOTHER | 0 | Jun 8, 2025 | clinicaltrials |
| NCT06861894 | Active Surveillance After Neoadjuvant Adebrelimab Combined With Chemoradiotherapy for Resectable ESCC | not yet recruiting | Phase 2 | 164 | Zhigang LiOTHER | 1 | May 15, 2025 | clinicaltrials |
Data updated 23 days agoSource updated Mar 19, 2026source: clinicaltrials